ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M
Reneuron Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.05p. Over the last year, Reneuron shares have traded in a share price range of 2.95p to 10.25p.

Reneuron currently has 57,173,760 shares in issue. The market capitalisation of Reneuron is £1.74 million. Reneuron has a price to earnings ratio (PE ratio) of -0.32.

Reneuron Share Discussion Threads

Showing 7951 to 7975 of 8900 messages
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
DateSubjectAuthorDiscuss
28/7/2020
18:27
Onceaday, Correct. There's plenty of room for more than one player here. And differences/advantages of each will emerge. Good time to buy IMO.
small crow
28/7/2020
16:26
If you read into the detail of yhe results, you will find it was a triple arm trial - they used a sham (no dose), low dose and high dose arm. Only the high dose arm showed meaningfull efficacy andonly a sub population showed comparable efficacy to RENE's ph2a results..

RENE will treat a further 9 patients at double dose in the ph2a extension trial. The fact that jCute had good results with the same type of hRPC cell validates RENEs work so far amd adds value. I think there will be a number of large pharmas keeping a very close eye (excuse the pun) on the extension trial. It's open label,unlike the jCyte ph2b, so they can announce tesults as they go.

Biotech investment is all about timing - it can take years (decades) for value inflection - it could be that RENE's time has finally arrived.

onceaday
27/7/2020
19:48
Well that new bloke brought in to do deals sure ain't cutting it is he ?
martinfrench
27/7/2020
16:17
There are quite a few US players looking to buy into RP drugs and only two companies who are well advanced in that field and happy to outlicence their drugs. I think jCyte success will only increase interest in a deal with Reneuron and the regulators doesn't seem to have a problem with only 10-20 patients in their study.
pawelkordala
27/7/2020
15:57
Oh well, makes rene look to be a loser. 74 patients as against 10! Much larger trial. Exozome the only hope?
rayrac
27/7/2020
13:18
hxxps://www.businesswire.com/news/home/20200727005222/en/
crt131
21/7/2020
15:00
Funding round soon
sambocoole
14/7/2020
17:00
He's got quite some money.
small crow
14/7/2020
15:58
Whatever, that’s quite a holding.
rayrac
14/7/2020
14:27
Typo or 15 months

5. Date on which the threshold was crossed or reached: 5 March 2019

hxxps://www.marketscreener.com/business-leaders/Richard-Griffiths-05J8QH-E/biography/

xow98
14/7/2020
14:21
Anyone know how that investor gets away with not filing until over 3 months after change?
small crow
29/6/2020
11:37
Encouraging results. It will be interesting to see the results come in from the new sample of patients once things begin - lessons should have been learned from sample 1 and so, hopefully, even more convincing improvements.
small crow
29/6/2020
08:07
martin - 18 months is only 1 patient hence not really comparable with the others - he's obviously done exceptionally well on the treatment.

Results remain very good for all patients (except those who suffered surgical problems obviously) but most striking to me is the improvement in the untreated eyes. Normally they would be expected to continue deteriorating to more or less full blindness, but here they're also improving quite markedly. Let's hope it continues.

supernumerary
29/6/2020
06:39
Pretty amazing jump from 12 to 18 months, if I have read it correctly on phone.

Also very pleased that one of the blinded patients got back to baseline

martinfrench
29/6/2020
06:17
More good news today, should help support the sp
ayl30
28/6/2020
10:29
Lauders, Thanks for that. I think exosomes will turnout to be very useful and valuable, but I've been wrong before! Let's hope we are inside the tent.
small crow
28/6/2020
05:37
Been having a look at the exosome companies and deals out of my own personal interest:

1) Sarepta Inks Agreement With Codiak to Develop Gene Therapies (already mentioned here) -

2) InnoCan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.

3) British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases.

4) Exopharm (ASX:EX1) reveals promising Plexaris anti-cancer results. + The company combined a typical lung cancer treatment drug called doxorubicin with its Plexaris exosome product to create a new treatment, dubbed Plexodox.

5) VivaZome Therapeutics and the University of Adelaide have entered into a series of agreements encompassing licensing of technology, access to stem cells and conduct of research, all in support of VivaZome’s mission to develop and commercialise exosome-based therapeutics.

6) MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development. + EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications.

7) Avalon GloboCare Partners with HydroPeptide. + Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy and exosome technology.

8) Orgenesis has added muscle-derived stem cells to its offering through a manufacturing joint venture with Revatis. The partnership will supply developers of autologous cell therapies with exosomes and other cellular products obtained from muscle-derived mesenchymal stem cells (mdMSCs).

9) Evox and Takeda sign deal to collaborate on rare disease treatments. + The targeted and non-targeted exosomes offer a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins.

10) Exosome specialist Exopharm (EX1) has reported some strong results for its Cevaris product in treating erectile dysfunction (ED).

These are just the first ten I found and there seem to be many more out there. Looks like this could be a very exciting place to be as RENE inks new deals and hopefully develops exosomes further for the benefit of many patients.

This is also worth a read:

lauders
25/6/2020
11:28
ReNeuron Group inks research evaluation deal with US firm - At 12.26 +3.50 (2.64%)
25 Jun, 11:48 BST

spurslegend1
25/6/2020
08:05
Yes that's the idea. They are part of cells in the body which carry payloads within the cell. RENE have managed to functionalist them as delivery systems..
bonzo
25/6/2020
07:57
I was much struck by this report. Not directly relevant, but I imagine there are researchers in labs all over the world trying to replicate these results. Could exosomes be used as carriers?
supernumerary
25/6/2020
07:50
??? An effective delivery system to the brain is a very valuable asset...
bonzo
25/6/2020
07:31
There we are!

But like Big Mac burgers, the smells not bad, but the taste...urgh

rayrac
24/6/2020
10:58
I have the sense that RENE is trying to go in this direction given the limits of its cash balance and an inability to self-finance its research through to marketable products. A similar deal like this would surely raise RENE's credibility with investors.
dickbush
23/6/2020
21:43
Big money still being paid for exosomes:



Gene therapy could be a game changer for various diseases, but it can be hobbled by its packaging, most often a virus to which some people are naturally immune. Sarepta Therapeutics is on the hunt for alternatives, and its latest target is a system the body’s cells use to communicate with each other: exosomes.

It is teaming up with Codiak Biosciences to develop engineered exosomes that can deliver gene therapy, gene editing or RNA-based treatments—all of which Sarepta is already working on. Under the two-year deal, Codiak will reel in up to $72.5 million in upfront and near-term license fees along with research funding, the pair said in a statement Monday. As usual, Codiak stands to pick up “significant” development and regulatory milestones, but the partners kept those numbers under wraps.

[ ... ]

supernumerary
19/6/2020
10:21
Exosome program is coming to the fore and we are in an increasing number of discussions with potential collaborators



RENE is one for the patient, but hopefully it will be very rewarding for patients, the company and investors when things come good! Have to think positive!

lauders
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older

Your Recent History

Delayed Upgrade Clock